Freenome

Freenome is dedicated to advancing early detection because early action saves lives. Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., but with routine screening and early intervention, it’s also one of the most preventable. 

The company is revolutionizing early cancer detection with its cutting-edge multiomics test, an innovative fusion of tumor and non-tumor biomarkers synthesized through advanced machine learning algorithms. Their liquid biopsy technology, with its leading sensitivity and specificity, has been validated in >10,000 patients.

Freenome’s suite of diagnostics is suitable for colon, lung, and other cancers. The ability to detect cancers that are significant drivers of morbidity and mortality at a phase when they can be treated effectively will greatly improve the lives of patients and their families.